Opus Genetics, Inc. (IRD)

NCM – Real Time Price. Currency in USD

4.00

+0.28 (7.53%)

At close: Jun 26, 2026, 4:00 PM EDT

4.00

0.00 (0.00%)

After-hours: Jun 26, 2026, 7:14 PM EDT

17.06.2026

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

16.06.2026

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics' Pipeline RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), hosted a Research and Development (R&D) Science Forum where management and leading IRD experts highlighted the Company's expanding gene therapy pipeline for severe retinal diseases.

02.06.2026

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET.

28.05.2026

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company.

27.05.2026

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m.

26.05.2026

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics NASDAQ: IRD is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets' 2026 Global Healthcare Conference.

13.05.2026

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m.

Videos

No Data

There is no data to display

Press releases

16.06.2026

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

02.06.2026

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

28.05.2026

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12.05.2026

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

Opus Genetics, Inc. (IRD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Videos

No Data

Press releases

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Videos

No Data

Press releases

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Search stocks

Opus Genetics, Inc. (IRD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Videos

No Data

Press releases

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Videos

No Data

Press releases

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update